CN107001477A - 经稳定化且自主的抗体vh结构域 - Google Patents

经稳定化且自主的抗体vh结构域 Download PDF

Info

Publication number
CN107001477A
CN107001477A CN201580067467.0A CN201580067467A CN107001477A CN 107001477 A CN107001477 A CN 107001477A CN 201580067467 A CN201580067467 A CN 201580067467A CN 107001477 A CN107001477 A CN 107001477A
Authority
CN
China
Prior art keywords
antibody
xaa
xaa xaa
single domain
molecule
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201580067467.0A
Other languages
English (en)
Chinese (zh)
Inventor
托拜厄斯·卡尔·科恩维克
伊格纳西奥·琼斯·阿夏尔
帕尔·伦纳特·诺德兰
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nanyang Technological University
Original Assignee
Nanyang Technological University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nanyang Technological University filed Critical Nanyang Technological University
Publication of CN107001477A publication Critical patent/CN107001477A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/005—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/80—Immunoglobulins specific features remaining in the (producing) cell, i.e. intracellular antibodies or intrabodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN201580067467.0A 2014-11-05 2015-11-04 经稳定化且自主的抗体vh结构域 Pending CN107001477A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SG10201407244P 2014-11-05
SG10201407244P 2014-11-05
PCT/SG2015/050432 WO2016072938A1 (en) 2014-11-05 2015-11-04 Stabilized and autonomous antibody vh domain

Publications (1)

Publication Number Publication Date
CN107001477A true CN107001477A (zh) 2017-08-01

Family

ID=55909517

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201580067467.0A Pending CN107001477A (zh) 2014-11-05 2015-11-04 经稳定化且自主的抗体vh结构域

Country Status (5)

Country Link
US (1) US11053302B2 (enExample)
EP (2) EP3215537B1 (enExample)
JP (1) JP6921743B2 (enExample)
CN (1) CN107001477A (enExample)
WO (1) WO2016072938A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR124917A1 (es) 2021-02-19 2023-05-17 Dotbio Pte Ltd Moléculas de unión a vegfa
WO2025257403A1 (en) 2024-06-14 2025-12-18 Dotbio Pte. Ltd. Virus-like particles

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005052002A2 (en) * 2003-11-20 2005-06-09 Massachusetts Institute Of Technology Single-domain antibodies and uses thereof
WO2007134050A2 (en) * 2006-05-09 2007-11-22 Genentech, Inc. Binding polypeptides with optimized scaffolds
CN101312988A (zh) * 2005-10-11 2008-11-26 杜门蒂斯有限公司 抗体多肽文库筛选和选择的抗体多肽类
CN101443043A (zh) * 2003-10-08 2009-05-27 杜门蒂斯有限公司 抗体组合物和方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4469774A (en) 1983-03-28 1984-09-04 E. I. Du Pont De Nemours And Company Positive-working photosensitive benzoin esters
US4542225A (en) 1984-08-29 1985-09-17 Dana-Farber Cancer Institute, Inc. Acid-cleavable compound
US4952394A (en) 1987-11-23 1990-08-28 Bristol-Myers Company Drug-monoclonal antibody conjugates
US5563250A (en) 1987-12-02 1996-10-08 Neorx Corporation Cleavable conjugates for the delivery and release of agents in native form
US5137877B1 (en) 1990-05-14 1996-01-30 Bristol Myers Squibb Co Bifunctional linking compounds conjugates and methods for their production
US5505931A (en) 1993-03-04 1996-04-09 The Dow Chemical Company Acid cleavable compounds, their preparation and use as bifunctional acid-labile crosslinking agents
US5618528A (en) 1994-02-28 1997-04-08 Sterling Winthrop Inc. Biologically compatible linear block copolymers of polyalkylene oxide and peptide units
US5767288A (en) 1996-01-05 1998-06-16 California Institute Of Technology Photolabile linkers and probes
DK2528944T3 (en) * 2010-01-29 2015-09-14 Morphosys Ag Rodent combinatorial antibody libraries

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101443043A (zh) * 2003-10-08 2009-05-27 杜门蒂斯有限公司 抗体组合物和方法
WO2005052002A2 (en) * 2003-11-20 2005-06-09 Massachusetts Institute Of Technology Single-domain antibodies and uses thereof
CN101312988A (zh) * 2005-10-11 2008-11-26 杜门蒂斯有限公司 抗体多肽文库筛选和选择的抗体多肽类
WO2007134050A2 (en) * 2006-05-09 2007-11-22 Genentech, Inc. Binding polypeptides with optimized scaffolds

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
MIN JEONG SEO等: ""Engineering antibody fragments to fold in the absence of disulfide bonds"", 《PROTEIN SCIENCE》 *
PIERRE A. BARTHELEMY等: ""Comprehensive Analysis of the Factors Contributing to the Stability and Solubility of Autonomous Human VH Domains"", 《THE JOURNAL OF BIOLOGICAL CHEMISTRY》 *

Also Published As

Publication number Publication date
WO2016072938A1 (en) 2016-05-12
EP3215537A1 (en) 2017-09-13
EP3215537B1 (en) 2022-01-05
JP6921743B2 (ja) 2021-08-18
US11053302B2 (en) 2021-07-06
EP4008729A1 (en) 2022-06-08
US20170320934A1 (en) 2017-11-09
EP3215537A4 (en) 2018-09-26
JP2018500879A (ja) 2018-01-18

Similar Documents

Publication Publication Date Title
US11466085B2 (en) Anti-PD-L1 nanobody, coding sequence and use thereof
CN111094338A (zh) 结合蛋白1
JP7520002B2 (ja) ヒト血清アルブミンに結合する単一ドメイン抗体
KR102406610B1 (ko) 혈액-뇌 장벽을 통과이동하는 인간화 항체 및 그의 용도
CN112552408B (zh) 靶向caix抗原的纳米抗体及其应用
US10906973B2 (en) Antibody variants transmigrating the blood-brain barrier and uses thereof
WO2012164372A1 (en) Recombinant anti-canine parvovirus antibody and uses thereof
CN120383679A (zh) 抗FAP单域抗体、Fc融合蛋白、免疫缀合物及其应用
US11053302B2 (en) Stabilized and autonomous antibody VH domain
CN114786720A (zh) TriAx抗体的组合物及其制备和使用方法
CN115997051A (zh) 蛋白质支架
JP2025534992A (ja) 新規なジスルフィド架橋を有する超安定抗体断片
JP2017014112A (ja) 抗サバイビン抗体又は抗体誘導体及びそれらの利用
CN115124621B (zh) 靶向pd-l1的纳米抗体及其制备方法和应用
CN114380907B (zh) 靶向cmtm6的纳米抗体及其制备方法和应用
KR20220075411A (ko) 글리보 - 계열 글리칸과 특이적으로 결합하는 단일 도메인 항체
CN117327191A (zh) 靶向cd20的笼状蛋白及其应用
TWI906795B (zh) 特異性結合Ｃｌａｕｄｉｎ １８.２的抗體及其製法和應用
CA3268444A1 (en) Ultrastable antibody fragments with a novel disuldide bridge
WO2025098472A1 (zh) 融合蛋白及其医药用途
HK40069791B (zh) 靶向caix抗原的纳米抗体及其应用
PL244962B1 (pl) Przeciwciało anty-FOLR1 i jego zastosowanie w medycynie
HK1053670A (en) Anti-egfrviii scfvs with improved cytotoxicity and yield, immunotoxins based thereon, and methods of use thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination